Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) rose 1.3% in pre-market trading after the company reported Q2 results.Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD).